Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect

With the advancement of a growing number of oncolytic viruses (OVs) to clinical development, drug delivery is becoming an important barrier to overcome for optimal therapeutic benefits. Host immunity, tumor microenvironment and abnormal vascularity contribute to inefficient vector delivery. A number of novel approaches for enhanced OV delivery are under evaluation, including use of nanoparticles, immunomodulatory agents and complex viral–particle ligands along with manipulations of the tumor microenvironment. This field of OV delivery has quickly evolved to bioengineering of complex nanoparticles that could be deposited within the tumor using minimal invasive image-guided delivery. Some of the strategies include ultrasound (US)-mediated cavitation-enhanced extravasation, magnetic viral complexes delivery, image-guided infusions with focused US and targeting photodynamic virotherapy. In addition, strategies that modulate tumor microenvironment to decrease extracellular matrix deposition and increase viral propagation are being used to improve tumor penetration by OVs. Some involve modification of the viral genome to enhance their tumoral penetration potential. Here, we highlight the barriers to oncolytic viral delivery, and discuss the challenges to improving it and the perspectives of establishing new modes of active delivery to achieve enhanced oncolytic effects.

• Publication year

  2017

• Venue

  Oncolytic Virotherapy

• Publication date

  2017-11-08

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.2147/OV.S145262PMID 29184854PMCID 5687448
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Incorporation of Viral Glycoprotein VSV-G Improves the Delivery of DNA by Erythrocyte Ghost into Cells Refractory to Conventional Transfection

  2017cited by this paper
• "Bottom-up" Construction of Multi-Polyprodrug-Arm Hyperbranched Amphiphiles for Cancer Therapy.

  2017cited by this paper
• MicroRNA-based Regulation of Picornavirus Tropism.

  2017cited by this paper
• Impact of Angiotensin Receptor Blocker Use on Overall Survival Among Patients Undergoing Resection for Pancreatic Cancer

  2017cited by this paper
• Enhancing Expression of Functional Human Sodium Iodide Symporter and Somatostatin Receptor in Recombinant Oncolytic Vaccinia Virus for In Vivo Imaging of Tumors

  2017cited by this paper
• Sickle Cells Abolish Melanoma Tumorigenesis in Hemoglobin SS Knockin Mice and Augment the Tumoricidal Effect of Oncolytic Virus In Vivo

  2016cited by this paper
• Delivery of improved oncolytic adenoviruses by mesenchymal stromal cells for elimination of tumorigenic pancreatic cancer cells

  2016cited by this paper
• Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic Viruses.

  2016cited by this paper
• Viral evasion of DNA-stimulated innate immune responses

  2016cited by this paper
• Candesartan attenuates angiogenesis in hepatocellular carcinoma via downregulating AT1R/VEGF pathway.

  2016cited by this paper
• A PTENtial cause for the selectivity of oncolytic viruses?

  2016cited by this paper
• Enhancing tumor penetration and targeting using size-minimized and zwitterionic nanomedicines.

  2016cited by this paper
• High-throughput screening to enhance oncolytic virus immunotherapy

  2016cited by this paper
• To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?

  2016cited by this paper
• Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer

  2016cited by this paper
• Oncolytic viruses: finally delivering

  2016cited by this paper
• Noninvasive Assessment of Losartan-Induced Increase in Functional Microvasculature and Drug Delivery in Pancreatic Ductal Adenocarcinoma1

  2016cited by this paper
• Tunneling nanotubes: an alternate route for propagation of the bystander effect following oncolytic viral infection

  2016cited by this paper
• Targeted Photodynamic Virotherapy Armed with a Genetically Encoded Photosensitizer

  2015cited by this paper
• Internal ribosome entry site-based vectors for combined gene therapy.

  2015cited by this paper
• Characterization of Magnetic Viral Complexes for Targeted Delivery in Oncology

  2015cited by this paper
• Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma.

  2015cited by this paper
• Oncolysis by paramyxoviruses: preclinical and clinical studies

  2015cited by this paper
• Oncolytic viruses: a new class of immunotherapy drugs

  2015cited by this paper
• Polymeric oncolytic adenovirus for cancer gene therapy.

  2015cited by this paper
• Tuning Surface Charge and PEGylation of Biocompatible Polymers for Efficient Delivery of Nucleic Acid or Adenoviral Vector.

  2015cited by this paper
• pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis.

  2015cited by this paper
• Cationic polymer nanoparticles and nanogels: from synthesis to biotechnological applications.

  2014cited by this paper
• MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus

  2014cited by this paper
• Analysis of glioblastoma tumor coverage by oncolytic virus-loaded neural stem cells using MRI-based tracking and histological reconstruction

  2014cited by this paper
• Pulsed Versus Continuous Application of the Prodrug 5-Fluorocytosine to Enhance the Oncolytic Effectiveness of a Measles Vaccine Virus Armed with a Suicide Gene

  2014cited by this paper
• Heterogeneous delivery is a barrier to the translational advancement of oncolytic virotherapy for treating solid tumors

  2014cited by this paper
• EPR: Evidence and fallacy.

  2014cited by this paper
• Oncolytic Adenovirus Expressing IL-23 and p35 Elicits IFN-γ- and TNF-α-Co-Producing T Cell-Mediated Antitumor Immunity

  2013cited by this paper
• Systemic tumor-specific gene delivery.

  2013cited by this paper
• Cavitation-enhanced delivery of a replicating oncolytic adenovirus to tumors using focused ultrasound.

  2013cited by this paper
• Vascular normalization as an emerging strategy to enhance cancer immunotherapy.

  2013cited by this paper
• Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth.

  2013cited by this paper
• Enhanced Tumor Uptake and Penetration of Virotherapy Using Polymer Stealthing and Focused Ultrasound

  2013cited by this paper
• An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma.

  2013cited by this paper
• EGFR-Targeted Adenovirus Dendrimer Coating for Improved Systemic Delivery of the Theranostic NIS Gene

  2013cited by this paper
• A review of the current status of siRNA nanomedicines in the treatment of cancer.

  2013cited by this paper
• Oncolytic adenovirus-induced autophagy: tumor-suppressive effect and molecular basis.

  2013cited by this paper
• Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.

  2013cited by this paper
• Therapeutic efficacy of a systemically delivered oncolytic adenovirus - biodegradable polymer complex.

  2013cited by this paper
• Mathematical Model for Radial Expansion and Conflation of Intratumoral Infectious Centers Predicts Curative Oncolytic Virotherapy Parameters

  2013cited by this paper
• Adenoviral vectors coated with PAMAM dendrimer conjugates allow CAR independent virus uptake and targeting to the EGF receptor.

  2013cited by this paper
• Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy.

  2013cited by this paper
• Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation.

  2013cited by this paper
• Adenovirus Detection by the cGAS/STING/TBK1 DNA Sensing Cascade

  2013cited by this paper
• Relevance of hypoxia in radiation oncology: pathophysiology, tumor biology and implications for treatment.

  2013cited by this paper
• Evaluation of Monocytes as Carriers for Armed Oncolytic Adenoviruses in Murine and Syrian Hamster Models of Cancer

  2012cited by this paper
• Systemic Delivery of Oncolytic Viruses: Hopes and Hurdles

  2012cited by this paper
• Ultrasound-induced cavitation enhances the delivery and therapeutic efficacy of an oncolytic virus in an in vitro model.

  2012cited by this paper
• ONCOLYTIC VIROTHERAPY

  2012cited by this paper
• Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials.

  2012cited by this paper
• Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1

  2012cited by this paper
• The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect.

  2011cited by this paper
• Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors

  2011cited by this paper
• Macrophage metalloelastase (MME) as adjuvant for intra-tumoral injection of oncolytic adenovirus and its influence on metastases development

  2011cited by this paper
• Engineering biomaterial systems to enhance viral vector gene delivery.

  2011cited by this paper
• Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα

  2011cited by this paper
• Tumor delivery of macromolecular drugs based on the EPR effect.

  2011cited by this paper
• Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy

  2011cited by this paper
• Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations.

  2010cited by this paper
• A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy

  2010cited by this paper
• A non-replicating oncolytic vector as a novel therapeutic tool against cancer.

  2010cited by this paper
• HPMA copolymer-cyclic RGD conjugates for tumor targeting.

  2010cited by this paper
• Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy

  2010cited by this paper
• Physical adsorption of PEG grafted and blocked poly-L-lysine copolymers on adenovirus surface for enhanced gene transduction.

  2010cited by this paper
• Silk-elastin-like hydrogel improves the safety of adenovirus-mediated gene-directed enzyme-prodrug therapy.

  2010cited by this paper
• Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth.

  2010cited by this paper
• Synergistic interaction between oncolytic viruses augments tumor killing.

  2010cited by this paper
• Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities.

  2010cited by this paper
• Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model

  2010cited by this paper
• Size and Shape of Protein Molecules at the Nanometer Level Determined by Sedimentation, Gel Filtration, and Electron Microscopy

  2009cited by this paper
• A Novel Recombinant Vaccinia Virus Expressing the Human Norepinephrine Transporter Retains Oncolytic Potential and Facilitates Deep-Tissue Imaging

  2009cited by this paper
• MicroRNAs and the regulation of vector tropism.

  2009cited by this paper
• Sustained viral gene delivery through core-shell fibers.

  2009cited by this paper
• In vivo imaging of extracellular matrix remodeling by tumor-associated fibroblasts

  2009cited by this paper
• Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded

  2008cited by this paper
• Cetuximab Retargeting of Adenovirus via the Epidermal Growth Factor Receptor for Treatment of Intraperitoneal Ovarian Cancer

  2008cited by this paper
• Oncolytic virotherapy.

  2008cited by this paper
• Epidermal growth factor (EGF) receptor targeted delivery of PEGylated adenovirus.

  2008cited by this paper
• Engineering microRNA responsiveness to decrease virus pathogenicity

  2008cited by this paper
• Reductive amination as a strategy to reduce adenovirus vector promiscuity by chemical capsid modification with large polysaccharides

  2008cited by this paper
• Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition

  2008cited by this paper
• Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.

  2007cited by this paper
• Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application.

  2007cited by this paper
• Microencapsulation of PEGylated Adenovirus within PLGA Microspheres for Enhanced Stability and Gene Transfection Efficiency

  2007cited by this paper
• VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth.

  2007cited by this paper
• Magnetic resonance–guided, real-time targeted delivery and imaging of magnetocapsules immunoprotecting pancreatic islet cells

  2007cited by this paper
• A Novel Chromogranin-A Promoter-Driven Oncolytic Adenovirus for Midgut Carcinoid Therapy

  2007cited by this paper
• A Mosaic Fiber Adenovirus Serotype 5 Vector Containing Reovirus σ1 and Adenovirus Serotype 3 Knob Fibers Increases Transduction in an Ovarian Cancer Ex vivo System via a Coxsackie and Adenovirus Receptor–Independent Pathway

  2007cited by this paper
• Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.

  2007cited by this paper
• Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer.

  2007cited by this paper
• Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus.

  2007cited by this paper
• Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells.

  2007cited by this paper
• Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses

  2007cited by this paper
• Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region

  2006cited by this paper

• Mesenchymal stem cell-derived small extracellular vesicles as a delivery vehicle of oncolytic reovirus.

  2025cites this paper
• Immune Checkpoint Inhibitors Combined with Oncolytic Virotherapy: Synergy, Heterogeneity, and Safety in Cancer Treatment

  2025cites this paper
• Resistance to oncolytic virotherapy: Multidimensional mechanisms and therapeutic breakthroughs (Review)

  2025cites this paper
• Nanoparticle-mediated delivery of oncolytic viral genomes: an innovative strategy for tumor-targeted immunotherapy

  2025cites this paper
• Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy

  2024cites this paper
• Enhancement of Therapeutic Potential of Oncolytic Virus with Homologous Tumor Cell Membranes for Pancreatic Cancer

  2024cites this paper
• Advances and Challenges in Interventional Immuno-Oncology Locoregional Therapies.

  2024cites this paper
• Oncolytic vaccinia virus and cancer immunotherapy

  2024cites this paper
• Viral therapy for targeted drug delivery to cancers: Recent advances, clinical and regulatory perspectives

  2024cites this paper
• Application of nanomedicines in tumor immunotherapy

  2024cites this paper
• Bioorthogonal oncolytic-virus nanovesicles combined bio-immunotherapy with CAR-T cells for solid tumors.

  2024cites this paper
• Systemic delivery of tannic acid-ferric-masked oncolytic adenovirus reprograms tumor microenvironment for improved therapeutic efficacy in glioblastoma

  2024cites this paper
• Nano Based-Oncolytic viruses for Cancer therapy.

  2023cites this paper
• Oncolytic viral therapy as promising immunotherapy against glioma

  2023cites this paper
• Flaviviruses in AntiTumor Therapy

  2023cites this paper
• The Viral Knock: Ameliorating Cancer Treatment with Oncolytic Newcastle Disease Virus

  2023cites this paper
• Autophagic-Related Proteins in Brain Gliomas: Role, Mechanisms, and Targeting Agents

  2023cites this paper
• Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy

  2023cites this paper
• Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy

  2022cites this paper
• The Landscape of Nanovectors for Modulation in Cancer Immunotherapy

  2022cites this paper
• Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We?

  2022cites this paper
• Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements

  2021cites this paper
• Expanding the role of interventional oncology for advancing precision immunotherapy of solid tumors

  2021cites this paper
• Imaging of Gene and Cell-Based Therapies: Basis and Clinical Trials

  2021cites this paper
• Cancer Immunotherapy Strategies: Basic Principles

  2021cites this paper
• Virus-inspired Strategies for Cancer Therapy.

  2021cites this paper
• Oncolytic Viruses as Nanomedicines against the Tumor Microenvironment

  2021cites this paper
• Humanized Mouse Models for the Advancement of Innate Lymphoid Cell-Based Cancer Immunotherapies

  2021cites this paper
• Delivery of cancer therapies by synthetic and bio-inspired nanovectors

  2021cites this paper
• Application of control theory in a delayed-infection and immune-evading oncolytic virotherapy.

  2020cites this paper
• The influence of oncolytic reovirus on the biological activities of umbilical cord-derived mesenchymal stem cells.

  2020cites this paper
• Repurposing Infectious Pathogen Vaccines in Cancer Immunotherapy

  2020cites this paper
• Oncolytic Viruses as Immunotherapeutic Agents

  2020cites this paper
• Clinical Application of Oncolytic Viruses: A Systematic Review

  2020cites this paper
• Clinical landscape of oncolytic virus research in 2020

  2020cites this paper
• Enhancing Oncolytic Virotherapy: Observations from a Voronoi Cell-Based Model.

  2020cites this paper
• Therapeutic application of the CRISPR system: current issues and new prospects

  2019cites this paper
• Current Immunotherapy Approaches for Malignant Melanoma

  2019cites this paper
• Oncolytic Adenoviruses in Gastrointestinal Cancers

  2018cites this paper
• Oncolytic virotherapy in upper gastrointestinal tract cancers

  2018cites this paper